TIDMAPH
RNS Number : 8801O
Alliance Pharma PLC
05 October 2023
For immediate release 5 October 2023
ALLIANCE PHARMA PLC
("Alliance" or the "Company")
Grant of Options to Directors
Alliance Pharma plc (AIM: APH), the international healthcare
group, announces that the Board has issued options over an
aggregate of 2,281,643 ordinary shares of 1 pence each in the
Company, on the recommendation of the Company's Remuneration
Committee, to the PDMRs detailed below, pursuant to the Company's
Long-Term Incentive Plan 2019.
Peter Butterfield, Chief Executive Officer, has been awarded
851,666 share options.
Andrew Franklin, Chief Financial Officer, has been awarded
568,866 share options.
Jeyan Heper, Chief Operating Officer, has been awarded 861,111
share options (250,000 of which have been awarded pursuant to his
joining of the Company earlier this year).
The awards have been granted at nil-cost and become exercisable
on 4 October 2026 subject always to continued employment and the
satisfaction of performance conditions based on EPS, TSR and ROCE
targets.
The net effect of the grant of Share Options and the resultant
option holdings are shown in the table below:
Name Share Options granted Total no. of options
over ordinary shares
now held
Peter Butterfield 851,666 4,057,553
---------------------- ----------------------
Andrew Franklin 568,866 2,845,373
---------------------- ----------------------
Jeyan Heper 861,111 861,111
---------------------- ----------------------
The notification below, made in accordance with the requirements
of the UK Market Abuse Regulation, provides further detail.
Notification and public disclosure of transactions by person
discharging managerial responsibilities.
Details of the person discharging managerial responsibilities/person
1 closely associated
a) Name Mr Peter Butterfield
--------------------------- ------------------------------------------------
Reason for the notification
2
-----------------------------------------------------------------------------
a) Position/status Chief Executive Officer - PDMR
--------------------------- ------------------------------------------------
b) Initial notification Initial Notification
/Amendment
--------------------------- ------------------------------------------------
Details of the issuer, emission allowance market participant,
3 auction platform, auctioneer or auction monitor
-----------------------------------------------------------------------------
a) Name Alliance Pharma plc
--------------------------- ------------------------------------------------
b) Legal Entity N/A
Identifier
--------------------------- ------------------------------------------------
Details of the transaction(s): section to be repeated for
4 (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
-----------------------------------------------------------------------------
a) Description Ordinary shares of 1.0 pence each
of the financial
instrument,
type of instrument
ISIN: GB0031030819
Identification
code
--------------------------- ------------------------------------------------
b) Nature of the Grant of Options
transaction
--------------------------- ------------------------------------------------
c) Currency GBP
--------------------------- ------------------------------------------------
d) Price(s) and Exercise Price No. of share options
volume(s) (p)
--------------------------- -------------------- --------------------------
Nil 851,666
----------------------------------------------------- --------------------------
e) Aggregated Grant of 851,666 options to acquire ordinary
information shares of 1 pence each at nil-cost.
- Aggregated
volume
- Price
- Aggregated
total
--------------------------- ------------------------------------------------
f) Date of the 4 October 2023
transaction
--------------------------- ------------------------------------------------
g) Place of the Outside of trading venue
transaction
--------------------------- ------------------------------------------------
Details of the person discharging managerial responsibilities/person
1 closely associated
a) Name Mr Andrew Franklin
--------------------------- ------------------------------------------------
Reason for the notification
2
-----------------------------------------------------------------------------
a) Position/status Chief Financial Officer - PDMR
--------------------------- ------------------------------------------------
b) Initial notification Initial Notification
/Amendment
--------------------------- ------------------------------------------------
Details of the issuer, emission allowance market participant,
3 auction platform, auctioneer or auction monitor
-----------------------------------------------------------------------------
a) Name Alliance Pharma plc
--------------------------- ------------------------------------------------
b) Legal Entity N/A
Identifier
--------------------------- ------------------------------------------------
Details of the transaction(s): section to be repeated for
4 (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
-----------------------------------------------------------------------------
a) Description Ordinary shares of 1.0 pence each
of the financial
instrument,
type of instrument
ISIN: GB0031030819
Identification
code
--------------------------- ------------------------------------------------
b) Nature of the Grant of Options
transaction
--------------------------- ------------------------------------------------
c) Currency GBP
--------------------------- ------------------------------------------------
d) Price(s) and Exercise Price No. of share options
volume(s) (p)
--------------------------- -------------------- --------------------------
Nil 568,866
----------------------------------------------------- --------------------------
e) Aggregated Grant of 568,866 options to acquire ordinary
information shares of 1 pence each at nil-cost.
- Aggregated
volume
- Price
- Aggregated
total
--------------------------- ------------------------------------------------
f) Date of the 4 October 2023
transaction
--------------------------- ------------------------------------------------
g) Place of the Outside of trading venue
transaction
--------------------------- ------------------------------------------------
Details of the person discharging managerial responsibilities/person
1 closely associated
a) Name Mr Jeyan Heper
--------------------------- -----------------------------------------------
Reason for the notification
2
----------------------------------------------------------------------------
a) Position/status Chief Operating Officer - PDMR
--------------------------- -----------------------------------------------
b) Initial notification Initial Notification
/Amendment
--------------------------- -----------------------------------------------
Details of the issuer, emission allowance market participant,
3 auction platform, auctioneer or auction monitor
----------------------------------------------------------------------------
a) Name Alliance Pharma plc
--------------------------- -----------------------------------------------
b) Legal Entity N/A
Identifier
--------------------------- -----------------------------------------------
Details of the transaction(s): section to be repeated for
4 (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
----------------------------------------------------------------------------
a) Description Ordinary shares of 1.0 pence each
of the financial
instrument,
type of instrument
ISIN: GB0031030819
Identification
code
--------------------------- -----------------------------------------------
b) Nature of the Grant of Options
transaction
--------------------------- -----------------------------------------------
c) Currency GBP
--------------------------- -----------------------------------------------
d) Price(s) and Exercise Price No. of share options
volume(s) (p)
--------------------------- -------------------- -------------------------
Nil 861,111
----------------------------------------------------- -------------------------
e) Aggregated Grant of 861,111options to acquire ordinary
information shares of 1 pence each at nil-cost.
- Aggregated
volume
- Price
- Aggregated
total
--------------------------- -----------------------------------------------
f) Date of the 4 October 2023
transaction
--------------------------- -----------------------------------------------
g) Place of the Outside of trading venue
transaction
--------------------------- -----------------------------------------------
For further information:
Alliance Pharma plc + 44 (0)1249 466966
Head of Investor Relations: Cora McCallum + 44 (0)1249 705168
ir@allianceph.com
+ 44 (0)20 7466
Buchanan 5000
Mark Court / Sophie Wills / Hannah Ratcliff
alliancepharma@buchanan.uk.com
Numis Securities Limited (Nominated Adviser + 44 (0)20 7260
and Joint Broker) 1000
Nominated Adviser: Freddie Barnfield /
Duncan Monteith / Sher Shah
+ 44 (0)20 7597
Investec Bank plc (Joint Broker) 5970
Patrick Robb / Maria Gomez de Olea
About Alliance
Alliance Pharma plc (AIM: APH) is a growing consumer healthcare
company . Our purpose is to empower people to make a positive
difference to their health and wellbeing by making our trusted and
proven brands available around the world.
We deliver organic growth through investing in our priority
brands and channels, in related innovation, and through selective
geographic expansion to increase the reach of our brands.
Periodically, we may look to enhance our organic growth through
selective, complementary acquisitions .
Headquartered in the UK, the Group employs around 285 people
based in locations across Europe, North America, and the Asia
Pacific region. By outsourcing our manufacturing and logistics we
remain asset-light and focused on maximising the value we can
bring, both to our stakeholders and to our brands. For more
information on Alliance, please visit our website :
www.alliancepharmaceuticals.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHUPGMWUUPWGAA
(END) Dow Jones Newswires
October 05, 2023 11:39 ET (15:39 GMT)
Alliance Pharma (LSE:APH)
Historical Stock Chart
From Mar 2024 to Apr 2024
Alliance Pharma (LSE:APH)
Historical Stock Chart
From Apr 2023 to Apr 2024
